Dr. Warren A. Chow
Claim this profileCity of Hope Comprehensive Cancer Center
Studies Melanoma
Studies Soft Tissue Sarcoma
13 reported clinical trials
31 drugs studied
Area of expertise
1Melanoma
Stage IV
Stage III
BRAF positive
2Soft Tissue Sarcoma
Stage IV
Stage III
HLA-A positive
Affiliated Hospitals
Clinical Trials Warren A. Chow is currently running
TAB004 + Toripalimab
for Solid Cancers
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB004 monotherapy and in combination with toripalimab and to describe the PK profile of toripalimab when administered with TAB004, 2) evaluate antitumor activity of TAB004 monotherapy and in combination with toripalimab; and 3) determine the immunogenicity of TAB004 monotherapy and in combination with toripalimab and to determine the immunogenicity of toripalimab when administered with TAB004. The exploratory objectives are to: 1) evaluate pharmacodynamic effects of TAB004 on its target receptor BTLA, as well as effects on the immune system; 2) evaluate biomarkers that may correlate with activity of TAB004 as monotherapy and in combination with toripalimab; 3) evaluate the utility of BTLA ligand, herpesvirus-entry mediator (HVEM), and additional exploratory biomarkers that could aid in selection of appropriate subjects for TAB004 monotherapy and in combination with toripalimab.
Recruiting1 award Phase 110 criteria
Immunotherapy + Chemotherapy
for Soft Tissue Sarcoma
This phase II trial compares the effect of immunotherapy with ipilimumab and nivolumab alone to their combination with cabozantinib in treating patients with soft tissue sarcoma that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply and may also prevent the growth of new blood vessels that tumors need to grow. By these actions it may help slow or stop the spread of cancer cells. Adding cabozantinib to the combination of ipilimumab and nivolumab may be better in stopping or slowing the growth of tumor compared to ipilimumab and nivolumab alone in patients with advanced soft tissue sarcoma.
Recruiting1 award Phase 2
More about Warren A. Chow
Clinical Trial Related4 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Warren A. Chow has experience with
- Nivolumab
- Ipilimumab
- GSK Adoptive Cell Therapy
- Letetresgene Autoleucel (lete-cel, GSK3377794)
- Cyclophosphamide
- Fludarabine
Breakdown of trials Warren A. Chow has run
Melanoma
Soft Tissue Sarcoma
Skin Cancer
Cutaneous Melanoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Warren A. Chow specialize in?
Warren A. Chow focuses on Melanoma and Soft Tissue Sarcoma. In particular, much of their work with Melanoma has involved Stage IV patients, or patients who are Stage III.
Is Warren A. Chow currently recruiting for clinical trials?
Yes, Warren A. Chow is currently recruiting for 10 clinical trials in Duarte California. If you're interested in participating, you should apply.
Are there any treatments that Warren A. Chow has studied deeply?
Yes, Warren A. Chow has studied treatments such as Nivolumab, Ipilimumab, GSK adoptive cell therapy.
What is the best way to schedule an appointment with Warren A. Chow?
Apply for one of the trials that Warren A. Chow is conducting.
What is the office address of Warren A. Chow?
The office of Warren A. Chow is located at: City of Hope Comprehensive Cancer Center, Duarte, California 91010 United States. This is the address for their practice at the City of Hope Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.